Structure Therapeutics Inc. American Depositary Shares Total Liabilities
Structure Therapeutics Inc. American Depositary Shares total liabilities. Based on the latest financial reports, Structure Therapeutics Inc. American Depositary Shares (GPCR) has total liabilities worth $71.01 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GPCR asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Structure Therapeutics Inc. American Depositary Shares (2020–2025)
Total liabilities of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025. This chart illustrates how Structure Therapeutics Inc. American Depositary Shares's total liabilities have evolved over time, based on quarterly financial data.
Structure Therapeutics Inc. American Depositary Shares Competitors by Total Liabilities
The table below lists competitors of Structure Therapeutics Inc. American Depositary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Goworld Co Ltd
SHE:000823
|
China | CN¥2.66 Billion |
|
YGSOFT Inc
SHE:002063
|
China | CN¥658.01 Million |
|
Global Ship Lease Inc
NYSE:GSL
|
USA | $1.04 Billion |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $152.24 Million |
|
TGS ASA SP.ADR/1
F:TGC0
|
Germany | €1.95 Billion |
|
Suning Commerce Group Co Ltd
SHE:002024
|
China | CN¥91.43 Billion |
|
Shenzhen Colibri Technologies Co Ltd
SHE:002957
|
China | CN¥2.92 Billion |
|
Quantum Computing Inc
NASDAQ:QUBT
|
USA | $20.66 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Structure Therapeutics Inc. American Depositary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Structure Therapeutics Inc. American Dep's balance sheet.
Liquidity & Leverage Metrics
Structure Therapeutics Inc. American Depositary Shares Total Liabilities Ratios Explained
Structure Therapeutics Inc. American Depositary Shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Structure Therapeutics Inc. American Depositary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Structure Therapeutics Inc. American Depositary Shares (2020–2025)
The table below shows the annual total liabilities of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $67.54 Million | +75.49% |
| 2024-12-31 | $38.49 Million | +32.48% |
| 2023-12-31 | $29.05 Million | -86.36% |
| 2022-12-31 | $212.99 Million | +21.09% |
| 2021-12-31 | $175.89 Million | +187.53% |
| 2020-12-31 | $61.17 Million | -- |
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more